FDA Approves Winrevair for Pulmonary Arterial Hypertension (PAH) in Adults
FDA approves a new treatment for a serious lung condition called pulmonary arterial hypertension.
The FDA has approved Winrevair for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to improve exercise capac…
A new FDA-approved injection helps adults with pulmonary arterial hypertension exercise longer, improve daily life, and lower the risk of ho…
